14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

Key Takeaways Explain This Topic AI

The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) represent the primary multidrug-resistant threats driving ICU-acquired morbidity and mortality.

For severe MRSA infections, vancomycin dosing targets an AUC24/MIC of 400 to 600 using Bayesian estimation; daptomycin is strictly contraindicated in MRSA pneumonia due to surfactant inhibition, while linezolid carries risks of myelosuppression, lactic acidosis, and serotonin syndrome.

In MERINO, piperacillin-tazobactam failed to show noninferiority to meropenem for ceftriaxone-resistant E. coli or Klebsiella bacteremia (30-day mortality 12.3% vs. 3.7%), so carbapenems are preferred for invasive ESBL infections.

Targeted therapeutics for carbapenem-resistant Enterobacterales (CRE) depend on carbapenemase class: serine beta-lactamases (KPC, OXA-48) respond to ceftazidime-avibactam or meropenem-vaborbactam, whereas metallo-beta-lactamases (NDM, VIM) require cefiderocol or ceftazidime-avibactam combined with aztreonam.

Stewardship rests on 48-72 hour antibiotic timeouts, short courses (7 days for VAP, about 4 days after source control for intra-abdominal infection, 7 days for uncomplicated gram-negative bacteremia per BALANCE), and procalcitonin-guided discontinuation.

Last updated: October 2026

The intensive care unit represents an ecological epicenter for the emergence and propagation of antimicrobial resistance. The convergence of critically ill immunocompromised hosts, invasive vascular and respiratory devices, and continuous broad-spectrum selective antibiotic pressure drives nosocomial transmission of multidrug-resistant (MDR) pathogens. Optimizing critical care outcomes requires mastery of molecular resistance mechanisms, precision dosing of targeted antimicrobial agents, and rigorous execution of antimicrobial stewardship principles.

The ESKAPE Pathogens Overview

The Infectious Diseases Society of America (IDSA) designated the ESKAPE pathogens as the primary group of virulent, multidrug-resistant bacterial species capable of escaping the biocidal activity of conventional antimicrobial therapies: E ── Enterococcus faecium (Vancomycin-Resistant Enterococci / VRE)

S ── Staphylococcus aureus (Methicillin-Resistant S. aureus / MRSA)
K ── Klebsiella pneumoniae (ESBL- and Carbapenemase-Producing / KPC)
A ── Acinetobacter baumannii (Carbapenem-Resistant / CRAB)
P ── Pseudomonas aeruginosa (Multidrug- and Difficult-to-Treat Resistance / DTR)
E ── Enterobacter cloacae complex (Inducible AmpC Beta-Lactamase Producers)
Gram-Positive MDR Pathogens: MRSA and VRE
1. Methicillin-Resistant Staphylococcus aureus (MRSA)

Resistance to methicillin and other β \beta β -lactams in MRSA is mediated by chromosomal acquisition of the mecA or mecC gene , which encodes an altered penicillin-binding protein termed PBP2a . PBP2a displays exceptionally low binding affinity for virtually all standard penicillins, cephalosporins, and carbapenems (with the exception of ceftaroline, an advanced-generation anti-MRSA cephalosporin).

Therapeutic Comparison for MRSA

Vancomycin:

Mechanism: Glycopeptide that binds the terminal D-Ala-D-Ala peptides of nascent peptidoglycan chains, inhibiting cell wall elongation.

Precision Dosing & TDM: The 2020 consensus guidelines from IDSA, ASHP, and SIDP eliminated traditional trough monitoring (target 15-20 mcg/mL) for severe MRSA infections due to poor correlation with clinical cure and a 3- to 4-fold increase in acute kidney injury. Therapeutic drug monitoring now mandates AUC/MIC-guided dosing , targeting a 24-hour area under the concentration-time curve to minimum inhibitory concentration ratio of AUC 24 / MIC = 400 to 600 mg ⋅ hr/L \text{AUC}_{24}/\text{MIC} = 400\text{ to }600\text{ mg}\cdot\text{hr/L} AUC 24 / MIC = 400 to 600 mg ⋅ hr/L (assuming a broth microdilution MIC ≤ 1 mg/L \le 1\text{ mg/L} ≤ 1 mg/L ), calculated using Bayesian pharmacokinetic software.

Daptomycin:

Mechanism: Lipopeptide that binds to bacterial cell membranes in a calcium-dependent manner, inserting its lipophilic tail to cause membrane depolarization, potassium ion efflux, and rapid cell death without lysis.

Clinical Role: Highly effective for MRSA bacteremia and right-sided infective endocarditis.

Warning

Daptomycin is strictly contraindicated in pneumonia. Daptomycin is irreversibly sequestered and inactivated by pulmonary surfactant, rendering it clinically ineffective in alveolar consolidations. Monitor serum creatine phosphokinase (CPK) weekly for skeletal myopathy and rhabdomyolysis, and remain alert for drug-induced acute eosinophilic pneumonia.

Linezolid:

Mechanism: Synthetic oxazolidinone that binds to the 50S ribosomal subunit (specifically the 23S rRNA), preventing assembly of the functional 70S initiation complex and halting protein synthesis.

Clinical Role: Excellent tissue distribution with a pulmonary epithelial lining fluid (ELF) to plasma ratio of ≈ 1.0 − 4.0 \approx 1.0-4.0 ≈ 1.0 − 4.0 , In the ZEPHyR trial it achieved higher clinical cure than vancomycin for MRSA nosocomial pneumonia without a mortality difference; IDSA/ATS guidelines accept either vancomycin or linezolid.

Toxicities: Reversible myelosuppression (principally thrombocytopenia) occurring typically after > 14 days > 14\text{ days} > 14 days of therapy; peripheral and optic neuropathy with prolonged courses; lactic acidosis mediated by inhibition of host mitochondrial protein synthesis; and weak, non-selective monoamine oxidase (MAO) inhibition, which predisposing patients to Serotonin Syndrome when co-administered with SSRIs, SNRIs, or meperidine.

2. Vancomycin-Resistant Enterococci (VRE)

Enterococcal resistance occurs predominantly in Enterococcus faecium . Resistance is driven by plasmid- or transposon-mediated acquisition of vanA or vanB gene clusters , which synthesize modified peptidoglycan precursors terminating in D-Ala-D-Lactate (D-Ala-D-Lac) rather than D-Ala-D-Ala. This single atomic change eliminates a crucial hydrogen bond, reducing vancomycin binding affinity by 1,000-fold.

VanA Phenotype: Confers high-level inducible resistance to both vancomycin and teicoplanin.

VanB Phenotype: Confers variable resistance to vancomycin with retained teicoplanin susceptibility.

Therapy: Linezolid ( 600 mg 600\text{ mg} 600 mg IV q12h) or high-dose Daptomycin ( 8 − 12 mg/kg/day 8-12\text{ mg/kg/day} 8 − 12 mg/kg/day IV). Standard daptomycin dosing ( 6 mg/kg 6\text{ mg/kg} 6 mg/kg ) is associated with rapid emergence of daptomycin-resistant enterococcal mutants.

Gram-Negative MDR Pathogens: ESBL, CRE, and Non-Fermenters
1. Extended-Spectrum Beta-Lactamases (ESBL)

ESBLs are plasmid-mediated enzymes (predominantly the CTX-M family , alongside SHV and TEM mutants) produced primarily by Escherichia coli , Klebsiella pneumoniae , and Proteus mirabilis . ESBLs hydrolyze third- and fourth-generation cephalosporins (ceftriaxone, ceftazidime, cefepime) and monobactams (aztreonam), but spare carbapenems and are inhibited in vitro by beta-lactamase inhibitors.

The Landmark MERINO Trial

Prior to 2018, observational studies suggested that piperacillin-tazobactam might serve as a "carbapenem-sparing" alternative for bacteremia caused by ESBL producers displaying in vitro susceptibility to piperacillin-tazobactam.

MERINO Trial (JAMA 2018): A multicenter, international, randomized controlled non-inferiority trial randomized 379 patients with ceftriaxone-resistant E. coli or K. pneumoniae bloodstream infections to receive either piperacillin-tazobactam ( 4.5 g 4.5\text{ g} 4.5 g IV q6h) or meropenem ( 1 g 1\text{ g} 1 g IV q8h).

Results: 30-day all-cause mortality was 12.3 % 12.3\% 12.3% in the piperacillin-tazobactam group versus 3.7 % 3.7\% 3.7% in the meropenem group (risk difference 8.6 % 8.6\% 8.6% ). Piperacillin-tazobactam failed to demonstrate non-inferiority; a later reanalysis with central MIC re-testing suggested that some excess deaths involved isolates that were actually nonsusceptible, but carbapenems remain preferred.

Practice Standard: Carbapenems (meropenem or imipenem-cilastatin) represent the undisputed gold standard for severe invasive infections caused by ESBL-producing Enterobacterales. Ertapenem is an effective once-daily option for non-pseudomonal infections outside the shock state.

2. Carbapenem-Resistant Enterobacterales (CRE)

CRE constitutes an urgent public health threat. Resistance to carbapenems occurs via two fundamental pathways: carbapenemase enzyme production (carbapenemase-producing CRE [CP-CRE]) or porin loss coupled with high-level ESBL/AmpC production. The molecular class of carbapenemase dictates antimicrobial selection: Ambler Classification of Carbapenemases

│
┌─────────────────────────────┼─────────────────────────────┐
▼ ▼ ▼
Class A Class B Class D
Serine Carbapenemases Metallo-Beta-Lactamases OXA-48-Like Enzymes
(e.g., KPC) (e.g., NDM, VIM, IMP) (e.g., OXA-48)
│ │ │
Ceftazidime-avibactam • Cefiderocol • Ceftazidime-avibactam
Meropenem-vaborbactam • Ceftazidime-avibactam + • Cefiderocol
Imipenem-relebactam Aztreonam (Vaborbactam & Relebactam
(Inhibited by novel BLIs) (Zinc-dependent active site) are INACTIVE)

Class A (Serine Carbapenemases, e.g., KPC): Klebsiella pneumoniae carbapenemases hydrolyze all penicillins, cephalosporins, monobactams, and carbapenems. They are inhibited by novel non- β \beta β -lactam β \beta β -lactamase inhibitors (avibactam, vaborbactam, relebactam).

Targeted Regimens: Ceftazidime-avibactam , Meropenem-vaborbactam , or Imipenem-cilastatin-relebactam .

Class B (Metallo-Beta-Lactamases [MBL], e.g., NDM, VIM, IMP): MBLs utilize a divalent zinc cofactor in their catalytic active site to hydrolyze all β \beta β -lactams except aztreonam. Avibactam, vaborbactam, and relebactam cannot inhibit MBLs.

Targeted Regimens: Ceftazidime-avibactam combined with aztreonam , the single-product aztreonam-avibactam (FDA-approved February 2025), or cefiderocol (a siderophore cephalosporin that enters bacteria via active ferric iron transporters). While aztreonam is immune to MBL hydrolysis, clinical MBL-producing strains co-produce serine ESBLs or AmpC enzymes that destroy aztreonam; avibactam neutralizes these serine enzymes, shielding aztreonam so it can eradicate the organism.

Class D (OXA-48-like Serine Carbapenemases): Endemic to the Mediterranean and Middle East. Avibactam inhibits OXA-48; vaborbactam and relebactam do not.

Targeted Regimen: Ceftazidime-avibactam .

3. Difficult-to-Treat Pseudomonas aeruginosa

Pseudomonas aeruginosa possesses remarkable intrinsic and acquired resistance, including transcriptional downregulation of the OprD outer membrane porin (conferring carbapenem resistance), derepression of chromosomal AmpC cephalosporinases , and upregulation of multi-component MexAB-OprM efflux pumps .

Ceftolozane-tazobactam: Engineered specifically to overcome pseudomonal resistance. Ceftolozane possesses high binding affinity for pseudomonal PBPs and is impervious to OprD porin mutations and active efflux pumps. It is the drug of choice for multidrug-resistant P. aeruginosa .

Alternatives: Ceftazidime-avibactam, Imipenem-cilastatin-relebactam, Cefiderocol.

4. Carbapenem-Resistant Acinetobacter baumannii (CRAB)

CRAB expresses Class D carbapenem-hydrolyzing oxacillinases (OXA-23, OXA-24/40, OXA-58). Therapeutic options are severely constrained.

Preferred: Sulbactam-Durlobactam plus Imipenem-Cilastatin or Meropenem: Durlobactam is a diazabicyclooctane beta-lactamase inhibitor that protects sulbactam from class A, C, and D enzymes, including OXA-type carbapenemases. Sulbactam-durlobactam was FDA-approved in May 2023 after the ATTACK trial showed lower 28-day mortality than colistin (19% vs. 32%) with less nephrotoxicity, and the IDSA AMR guidance names it the preferred agent for invasive CRAB infection, given with imipenem-cilastatin or meropenem.

Alternative: High-Dose Ampicillin-Sulbactam: Sulbactam has intrinsic activity against Acinetobacter by binding PBP1 and PBP3. If sulbactam-durlobactam is unavailable, IDSA suggests high-dose ampicillin-sulbactam ( 27 g/day , providing 9 g/day of sulbactam ) combined with at least one other active agent such as minocycline , tigecycline , polymyxin B , or cefiderocol .

Polymyxin Toxicity: Colistin (polymyxin E) and Polymyxin B function as cationic detergents that disrupt outer membrane lipopolysaccharides. They carry a 30% to 50% incidence of acute kidney injury (acute tubular necrosis) and neurotoxicity (paresthesias, muscle weakness, and neuromuscular blockade).

Master Resistance Mechanisms and Targeted Formulary

Pathogen & Resistance Phenotype Molecular Resistance Mechanism First-Line Targeted Agent(s) Key Clinical Pearls & Toxicities

MRSA mecA/mecC encoding altered PBP2a Vancomycin (AUC/MIC 400-600) or Linezolid (pneumonia) Daptomycin inactivated by surfactant (no pneumonia); Linezolid causes thrombocytopenia and serotonin syndrome.

VRE ( E. faecium ) vanA/vanB peptidoglycan alteration to D-Ala-D-Lac Linezolid or High-dose Daptomycin ( 8 − 12 mg/kg 8-12\text{ mg/kg} 8 − 12 mg/kg ) Standard-dose daptomycin breeds rapid resistance; monitor CPK.

ESBL ( E. coli, K. pneumoniae ) CTX-M, TEM, SHV plasmid enzymes Meropenem or Imipenem-cilastatin MERINO trial proved piperacillin-tazobactam has higher 30-day mortality despite in vitro sensitivity.

CRE (KPC Class A) Serine carbapenemase Ceftazidime-avibactam or Meropenem-vaborbactam Sparing polymyxins reduces mortality and acute kidney injury.

CRE (NDM / MBL Class B) Zinc-dependent metallo-beta-lactamase Ceftazidime-avibactam + aztreonam , aztreonam-avibactam , or cefiderocol Avibactam protects aztreonam from co-expressed serine enzymes.

CRE (OXA-48 Class D) OXA-48 carbapenemase Ceftazidime-avibactam Vaborbactam and relebactam have NO activity against OXA-48.

MDR P. aeruginosa OprD loss + AmpC + MexAB efflux Ceftolozane-tazobactam Retains activity despite porin loss; relebactam is an alternative.

CRAB ( A. baumannii ) OXA-23/24/58 oxacillinases Sulbactam-durlobactam + imipenem or meropenem (preferred) Alternative: high-dose ampicillin-sulbactam (9 g/day sulbactam) plus a second active agent.

Antimicrobial Stewardship Principles in the ICU

Aggressive antimicrobial stewardship programs (ASP) in the critical care setting optimize clinical cure rates, minimize selective pressure for resistant mutants, curtail Clostridioides difficile colitis, and avoid drug-induced toxicities.

1. Rapid Diagnostic Technologies (RDTs)

Multiplex real-time polymerase chain reaction (PCR) blood culture identification panels (e.g., FilmArray BCID) and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) identify microbial species and resistance genes (e.g., mecA , vanA , blaKPC , blaNDM ) within 1 to 2 hours of blood culture positivity, enabling targeted antibiotic optimization 24 to 48 hours before conventional phenotypic susceptibility results become available.

2. Algorithmic De-escalation & The 48-72 Hour Antibiotic Timeout

Clinicians should conduct a formal "Antibiotic Timeout" at 48 to 72 hours :

Review definitive microbiological cultures, sensitivities, and patient clinical trajectory.

Transition from dual Gram-negative coverage (e.g., anti-pseudomonal beta-lactam plus aminoglycoside or fluoroquinolone) to monotherapy.

Discontinue empiric MRSA coverage (vancomycin or linezolid) if nasal MRSA PCR screening is negative or cultures fail to isolate staphylococci (nasal MRSA PCR possesses a negative predictive value > 96 − 98 % > 96-98\% > 96 − 98% for MRSA pneumonia).

Narrow spectrum: shift from broad-spectrum carbapenems or cefepime to targeted narrow-spectrum agents (e.g., ampicillin, cefazolin, or ceftriaxone) based on confirmed susceptibilities.

3. Evidence-Based Short Duration of Therapy

Historical 14- to 21-day antibiotic regimens increase resistance without improving cure rates. Randomized trials support defined short-course therapies: Evidence-Based Short Course Durations in the ICU

┌──────────────────────────────────────────────┬──────────────────┐
│ Clinical Infection Syndrome │ Recommended Days │
├──────────────────────────────────────────────┼──────────────────┤
│ Ventilator-Associated Pneumonia (VAP) │ 7 to 8 days │
│ Intra-Abdominal Infection (Source Controlled)│ 4 to 7 days │
│ Gram-Negative Bacteremia (Source Controlled) │ 7 days │
│ Community-Acquired Pneumonia │ At least 5 days │
│ Catheter-Related Bloodstream (Uncomplicated) │ 5 to 7 days │
└──────────────────────────────────────────────┴──────────────────┘

VAP Duration: Multiple randomized trials demonstrate that 7 to 8 days of therapy yields identical clinical cure, recurrent pneumonia rates, and hospital mortality compared to 14 days, with significantly fewer resistant superinfections.

Intra-Abdominal Infections (The STOP-IT Trial, NEJM 2015): In 518 patients with complicated intra-abdominal infection undergoing adequate source control, a short antibiotic course of 4 days produced identical outcomes (rates of surgical site infection, recurrent sepsis, or death) compared to historical courses averaging 8 to 10 days.

Bloodstream Infection: Several trials showed 7 days noninferior to 14 days for uncomplicated gram-negative bacteremia, and the large BALANCE trial (NEJM 2025; 3,608 hospitalized patients, including ICU patients) found 7 days noninferior to 14 days for bacteremia overall (90-day mortality 14.5% vs. 16.1%). BALANCE excluded Staphylococcus aureus , which still requires at least 14 days of IV therapy (longer if complicated).

Community-Acquired Pneumonia: ATS/IDSA 2019 advises at least 5 days and clinical stability before stopping; severe or complicated pneumonia (empyema, S. aureus , Pseudomonas ) may need longer.

4. Procalcitonin-Guided Discontinuation

Procalcitonin (PCT) is a calcitonin peptide precursor synthesized ubiquitously by parenchymal tissues in response to bacterial endotoxin and pro-inflammatory cytokines (IL-1, TNF- α \alpha α ), while being suppressed by viral interferon- γ \gamma γ . Serum levels rise rapidly within 3 to 6 hours and possess a biological half-life of 24 hours.

Discontinuation Algorithm: Antibiotic therapy should be discontinued when serum procalcitonin decreases by ≥ 80 % \ge 80\% ≥ 80% from peak or reaches an absolute cutoff of < 0.25 to 0.5 mcg/L < 0.25\text{ to }0.5\text{ mcg/L} < 0.25 to 0.5 mcg/L , provided the patient exhibits objective clinical stabilization.

Trial Evidence: In PRORATA (Lancet 2010) and SAPS (Lancet Infect Dis 2016), procalcitonin algorithms reduced antibiotic exposure by about 2 to 3 days without worsening outcomes; only SAPS showed lower 28-day mortality, and ADAPT-Sepsis (JAMA 2025) confirmed shorter antibiotic courses with daily PCT-guided stopping. The 2026 SSC suggests procalcitonin plus clinical evaluation to decide when to stop, but not when to start, antimicrobials.

Antimicrobial Stewardship ICU Action Checklist

Pre-Prescription Phase: Obtain dedicated sterile cultures (at least two sets of blood cultures, sputum/bronchoalveolar lavage, urine) prior to antimicrobial administration, avoiding delays > 45 > 45 > 45 minutes in septic shock.

Empiric Selection: Formulate empiric coverage based on local antibiograms, prior patient colonization, and recent antimicrobial exposures within the preceding 90 days.

48-to-72-Hour Timeout: Formally re-evaluate therapy once microbiological identities and PCR panels return; systematically de-escalate broad empiric double-coverage to a single narrow-spectrum agent.

Vancomycin Bayesian TDM: Transition from static trough measurements to software-guided AUC 24 / MIC \text{AUC}_{24}/\text{MIC} AUC 24 / MIC calculations (target 400-600) to mitigate nephrotoxicity.

Enforce Hard Stop Dates: Pre-specify short course durations in electronic medical records (7 days for VAP, about 4 days after source control for intra-abdominal sepsis, 7 days for uncomplicated non-S. aureus bacteremia).

Procalcitonin Liberation Protocol: Discontinue antibiotics when procalcitonin clears by ≥ 80 % \ge 80\% ≥ 80% or drops < 0.25 − 0.5 mcg/L < 0.25-0.5\text{ mcg/L} < 0.25 − 0.5 mcg/L .